WaveMan
WaveMan · Company
CNSP · Cns Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CNSP CNS Pharmaceuticals (CNSP) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001729427
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
7
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $0 priced

What the filings say about CNSP

Insiders, 180 days
+$44.0K net bought
2 buyers

CNS Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CNS Pharmaceuticals, Inc. insiders bought a net $44.0K of stock across 31 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Charles Faith L.
Director
BUY
2026-05-20 SECtraded 2026-05-18
7,100
$34.0K
-8.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 7,100 shares held after it.
  • 1 other insider bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Charles Faith L. bought about $34.0K of CNSP on May 18, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 7 funds added in the latest 13F quarter.
Fisher Michal
Director
BUY
2026-08-18 SECtraded 2026-05-18
2,000
$10.0K
-20.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 2,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fisher Michal bought about $10.0K of CNSP on May 18, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 7 funds added in the latest 13F quarter.
Gumulka Jerzy
Director
BUY
2024-02-06 SECtraded 2024-02-01
33,333
$10.0K
-99.9%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Apr 19, 2023.
  • +121.5% median (+121.5% mean) 90-day return after 2 previous buys.
  • The trade is 77.5% of the 43,006 shares held after it.
  • 3 other insiders bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Gumulka Jerzy bought about $10.0K of CNSP on Feb 1, 2024; 3 other insiders bought within 30 days and 7 funds added in the latest 13F quarter.
Evans Carl Anthony
Director
BUY
2024-02-06 SECtraded 2024-02-01
33,333
$10.0K
-99.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 99.6% of the 33,458 shares held after it.
  • 3 other insiders bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Evans Carl Anthony bought about $10.0K of CNSP on Feb 1, 2024; 3 other insiders bought within 30 days and 7 funds added in the latest 13F quarter.
Downs Christopher
Chief Financial Officer
BUY
2024-02-06 SECtraded 2024-02-01
66,666
$20.0K
-99.9%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Aug 22, 2023.
  • -46.6% median (-30.9% mean) 90-day return after 4 previous buys.
  • The trade is 64.5% of the 103,438 shares held after it.
  • 3 other insiders bought within 30 days.
  • 7 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Downs Christopher bought about $20.0K of CNSP on Feb 1, 2024; 3 other insiders bought within 30 days and 7 funds added in the latest 13F quarter.
31 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 26 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$44.0K over 180 days
more than 72% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
7 funds bought in last quarter
below 91% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 89% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CNSP

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-42.5%12M
-74%-48%-22%+4%2025-102025-122026-022026-042026-062026-082026-10 2026-05-18 · Charles Faith L. bought $34.0K2026-05-18 · Fisher Michal bought $10.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CNSP: institutional holders (13F)

13F holdings, latest reported quarter
Stonepine Capital Management, LLC
1,387,494 sh
$6.6M
Ikarian Capital, LLC
135,830 sh
$649.3K
ADAR1 Capital Management, LLC
70,000 sh
$334.6K
BOOTHBAY FUND MANAGEMENT, LLC
13,524 sh
$64.6K
VANGUARD FIDUCIARY TRUST CO
10,226 sh
$48.9K

Congress trades in CNSP

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CNSP planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CNSP mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$36.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$33.4K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$3.0K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · John M. Climaco
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$624.3K
$846.9K
$671.7K
-47%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $44.0K bought by insiders over 180 days, 7 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CNSP financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.02x
current debt only, 2022-11-14 (44 months older than the period end); equity 2026-06-30
Cash flow to debt
-29.82x
TTM operating cash flow over current debt only, 2022-11-14 (44 months older than the period end)
Return on equity
-5.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-4.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-108.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
-$12.8M
market value at close 2026-10-26 on 2026-08-11 shares, plus current debt only, 2022-11-14 (44 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$16.0M-$14.9M-$18.9M-$15.3M
Net income-$16.0K-$14.9K-$18.9K-$15.3M
EPS (diluted)n/an/an/a-11.22
Operating cash flow-$13.8M-$17.1M-$14.1M-$10.6M
Cash$7.2M$6.5M$548.7K$10.1M
SEC XBRL, fiscal years, as known on 2026-10-28

CNSP Stock Sonar score 5/7 axes

Find similar shapesCompare

CNSP ranks highest on risk and compliance (92nd percentile) and insider conviction (76th), and lowest on institutional and government (9th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
60
Inputs
  • Return on equity-5.5% · 79 pct, sector of 545
  • Return on assets-4.7% · 78 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-108.0% · 23 pct, sector of 576
Financial health
43
Inputs
  • Debt to equity0.02x · 70 pct, sector of 352
  • Cash flow to debt-29.82x · 16 pct, sector of 371
Insider conviction
76
Inputs
  • Net Form 4 buying (codes P and S), 180d$44K · 71 pct, sector of 429
  • Insider buyers, 180d2 · 81 pct, sector of 438
Institutional and government
9
Inputs
  • Funds adding, latest quarter7 · 9 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
92
Inputs
  • Short interest, % of float+0.1% · 92 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CNSP filings, in plain words

Are CNS Pharmaceuticals insiders buying or selling CNSP?

In the 180 days to 2026-10-28, CNS Pharmaceuticals insiders were net buyers, a net $44.0K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, CNS Pharmaceuticals insiders were net buyers of CNSP, a net $44.0K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies